Clinical Trial Update: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety results for prolonged-release dalfampridine (dalfampridine-ER) in people with multiple sclerosis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dalfampridine-ER (dalfampridine)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-27